CN108349988B - 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物 - Google Patents

作为磷酸肌醇3-激酶抑制剂的三环杂环化合物 Download PDF

Info

Publication number
CN108349988B
CN108349988B CN201680058333.7A CN201680058333A CN108349988B CN 108349988 B CN108349988 B CN 108349988B CN 201680058333 A CN201680058333 A CN 201680058333A CN 108349988 B CN108349988 B CN 108349988B
Authority
CN
China
Prior art keywords
alkyl
reaction mixture
added
meoh
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680058333.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN108349988A (zh
Inventor
斯蒂芬·约瑟夫·沙特勒沃斯
弗兰克·亚历山德勒·希尔瓦
亚历山大·理查德·利亚姆·塞西尔
瑞可·彼得·亚历山大
爱丽丝·伊丽莎白·加特兰
丹尼尔·约翰·芬尼莫尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fukang Biotechnology Shanghai Co ltd
Original Assignee
Karus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karus Therapeutics Ltd filed Critical Karus Therapeutics Ltd
Publication of CN108349988A publication Critical patent/CN108349988A/zh
Application granted granted Critical
Publication of CN108349988B publication Critical patent/CN108349988B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201680058333.7A 2015-08-19 2016-08-19 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物 Active CN108349988B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1514754.9 2015-08-19
GBGB1514754.9A GB201514754D0 (en) 2015-08-19 2015-08-19 Compounds
PCT/GB2016/052581 WO2017029521A1 (en) 2015-08-19 2016-08-19 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors

Publications (2)

Publication Number Publication Date
CN108349988A CN108349988A (zh) 2018-07-31
CN108349988B true CN108349988B (zh) 2021-10-01

Family

ID=54258853

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680058333.7A Active CN108349988B (zh) 2015-08-19 2016-08-19 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物

Country Status (9)

Country Link
US (1) US10442815B2 (https=)
EP (1) EP3337807A1 (https=)
JP (1) JP2018528942A (https=)
CN (1) CN108349988B (https=)
AU (1) AU2016307889A1 (https=)
CA (1) CA2995909A1 (https=)
GB (1) GB201514754D0 (https=)
MX (1) MX2018001992A (https=)
WO (1) WO2017029521A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012002059A (es) 2009-08-20 2012-04-19 Karus Therapeutics Ltd Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa.
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
JP7290627B2 (ja) 2017-08-17 2023-06-13 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
GB201909468D0 (en) 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer
TW202134245A (zh) 2019-12-05 2021-09-16 美商邊際分析公司 稠合三環雜環化合物及其用途
TWI885039B (zh) 2020-01-13 2025-06-01 美商邊際分析公司 經取代吡唑并嘧啶及其用途
WO2022169882A1 (en) 2021-02-03 2022-08-11 Verge Analytics, Inc. Methods and treatment of viral infection caused by sars-cov-2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102498115A (zh) * 2009-08-20 2012-06-13 卡鲁斯治疗有限公司 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物
WO2015121657A1 (en) * 2014-02-12 2015-08-20 Karus Therapeutics Ltd Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445742A1 (de) 1963-11-06 1968-12-19 Bayer Ag Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
US4017500A (en) 1973-07-16 1977-04-12 Schering Corporation Certain 8-amino-1,7-naphthyridines
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
KR100774855B1 (ko) 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
WO2002002551A1 (en) 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2557541C (en) 2004-02-26 2014-12-16 Aska Pharmaceutical Co., Ltd. Pyrimidine derivatives
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP2354140A1 (en) 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
KR20090021155A (ko) 2006-04-26 2009-02-27 에프. 호프만-라 로슈 아게 Ｐｉ3ｋ 억제제로서의 피리미딘 유도체
TW200801012A (en) 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
WO2008001076A1 (en) * 2006-06-26 2008-01-03 Ucb Pharma S.A. Fused thiazole derivatives as kinase inhibitors
KR20090087027A (ko) 2006-11-13 2009-08-14 일라이 릴리 앤드 캄파니 염증 질환 및 암의 치료를 위한 티에노피리미디논
AU2008210455A1 (en) 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as kinase inhibitors
EP2139332A4 (en) 2007-03-28 2010-04-21 Merck Sharp & Dohme SUBSTITUTED PYRIDO [2,3-D] PYRIMIDIN DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
WO2008150827A1 (en) 2007-05-29 2008-12-11 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
US20110201608A1 (en) 2008-08-05 2011-08-18 Boehringer Ingelheim International Gmbh Substituted naphthyridines and use thereof as medicines
WO2010037765A2 (en) 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
EP2459543B1 (en) 2009-07-29 2017-08-30 Karus Therapeutics Limited Benzo[e][1,3]oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
EP4119551A1 (en) 2011-07-27 2023-01-18 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine compounds
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
WO2014081718A1 (en) 2012-11-20 2014-05-30 Genentech, Inc. Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
PT2994465T (pt) 2013-05-10 2018-10-25 Karus Therapeutics Ltd Novos inibidores de histona desacetilase
CA2914284A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2014210354A1 (en) * 2013-06-28 2014-12-31 Genentech, Inc. Azaindazole compounds as inhibitors of t790m containing egfr mutants
ES2818933T3 (es) 2013-10-10 2021-04-14 Acetylon Pharmaceuticals Inc Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin
GB201321730D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321729D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102498115A (zh) * 2009-08-20 2012-06-13 卡鲁斯治疗有限公司 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物
WO2015121657A1 (en) * 2014-02-12 2015-08-20 Karus Therapeutics Ltd Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors

Also Published As

Publication number Publication date
EP3337807A1 (en) 2018-06-27
GB201514754D0 (en) 2015-09-30
US20180244685A1 (en) 2018-08-30
US10442815B2 (en) 2019-10-15
CA2995909A1 (en) 2017-02-23
WO2017029521A1 (en) 2017-02-23
CN108349988A (zh) 2018-07-31
JP2018528942A (ja) 2018-10-04
AU2016307889A1 (en) 2018-03-08
MX2018001992A (es) 2018-06-19

Similar Documents

Publication Publication Date Title
CN108349988B (zh) 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物
CN112105419B (zh) 稠环化合物
CN113164775B (zh) 用于迅速加速性纤维肉瘤多肽的靶向降解的多环化合物和方法
KR102013512B1 (ko) 신규 3-인돌 치환 유도체, 제약 조성물 및 사용 방법
CN114948963B (zh) 蛋白激酶抑制剂苯并内酰胺化合物
KR20240021197A (ko) Ras 억제제로서 유용한 퀴나졸린 유도체
CN105732636B (zh) 杂芳化合物及其在药物中的应用
CN108137613B (zh) 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物
WO2023280254A1 (zh) 一种tead抑制剂
WO2024088408A1 (zh) 一种含氮杂环化合物、其药学上可接受的盐及其制备方法与应用
TW202525800A (zh) Ｒａｓ抑制劑
JP2021519308A (ja) 転写活性化タンパク質のイミダゾピペラジン阻害剤
CN110621670A (zh) 作为布鲁顿氏酪氨酸激酶的抑制剂的苯并氮杂卓类似物
CN105541693B (zh) 芳杂环类衍生物及其在药物上的应用
KR20240091009A (ko) 신규 스피로 화합물
CN115873000A (zh) 异喹啉酮类及喹唑啉酮类化合物及其组合物和用途
CN118201918A (zh) 用于治疗癌症和纤维化疾病的ddr1和ddr2抑制剂
CN117425658A (zh) 用作ras抑制剂的喹唑啉衍生物
HK40010369B (zh) 为jak抑制剂的5-氯-2-二氟甲氧基苯基吡唑并嘧啶化合物
HK40010369A (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
HK40035008A (en) Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220822

Address after: Building 26, Lane 1000, Zhangheng Road, Pudong New Area, Shanghai

Patentee after: Fukang (Shanghai) Health Technology Co.,Ltd.

Address before: Oxfordshire

Patentee before: KARUS THERAPEUTICS Ltd.

TR01 Transfer of patent right
CP03 Change of name, title or address

Address after: 201318 No. 1-28, Lane 588, Tianxiong Road, Pudong New Area, Shanghai

Patentee after: Fukang Biotechnology (Shanghai) Co.,Ltd.

Country or region after: China

Address before: 201203 Shanghai Pudong New Area Zhangheng Road 1000 Lane 26 Building

Patentee before: Fukang (Shanghai) Health Technology Co.,Ltd.

Country or region before: China

CP03 Change of name, title or address